Navigation Links
Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
Date:10/24/2007

-Data from Phase IIIb clinical study presented at CHEST 2007 on concomitant

use of Perforomist(TM) Inhalation Solution with tiotropium for COPD

treatment-

NAPA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Data presented today at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP), demonstrate concomitant use of nebulized formoterol fumarate and tiotropium provided improved bronchodilation over tiotropium monotherapy and was well-tolerated in this clinical study. The only commercially available version of nebulized formoterol fumarate is Perforomist(TM) Inhalation Solution, which is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

Formoterol fumarate is a rapid and long-acting beta2-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation and has twenty years of worldwide experience. Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of this molecule. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

Results presented were from "Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol and Tiotropium in COPD," a randomized, placebo-controlled Phase IIIb trial. The trial demonstrated that concomitant therapy with twice-daily nebulized formoterol fumarate (FFIS) and once-daily tiotropium provided patients with statistically significant and clinically relevant improvements in bronchodilation over treatment with tiotropium alone. In this six-week study, patients receiving concomitant therapy with nebulized FFIS and tiotropium experienced fewer adverse events or COPD exacerbations than patients receiving placebo or tiotropium monotherapy.

According to Donald P. Tashkin, MD, FACP, FCCP, Professor of Medi
'/>"/>

SOURCE Dey, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Conn. , May 27, 2015  With all ... for the services they provide to keep patients healthy ... The ripple effect of the Affordable Care Act continues ... health insurance payer partners, making it more important than ... of communication with those they contract with for patient ...
(Date:5/27/2015)... 2015 The global vitreoretinal surgery ... with analysis and forecast of revenue. This market is ... estimated to grow at a CAGR of 8.9 % ... TOC of the global vitreoretinal surgery devices market report ... This report also provides a glimpse of the market ...
(Date:5/27/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) has announced the ... Growth, Trends And Forecasts (2014 - 2019)" company ... detailed type of imaging that customs a low-dose x-ray ... mammogram, is used to support in the early detection ... (radiograph) is a noninvasive medical test that helps physicians ...
Breaking Medicine Technology:Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2
... NEW YORK, Oct. 27 Intercept Pharmaceuticals, Inc., today ... double-blind Phase II clinical trial of INT-747 in ... evaluated the effects of adding one of three doses ... in patients who did not respond adequately to UDCA ...
... Pharmaceuticals, Inc. today announced $4.5 million in Series A and ... complete the company,s ongoing Phase I/IIa trial of BP-GMAX-CD1 in ... for Phase IIb trials. The company anticipates reporting initial results ... new funding brings the total raised to date to $8.5 ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 3Bellicum Pharmaceuticals Announces $4.5 Million in New Funding 2
(Date:5/27/2015)... 2015 While hair transplantation has been ... new pilot study conducted by a physician member of ... found hair follicle grafting can help treat patients with ... funded by ISHRS, which offers research grants for the ... , In the past decade, numerous scientific studies ...
(Date:5/27/2015)... May 27, 2015 The new ... include: Why investors should consider oil and gas investing, ... why wells are drilled, industry news, IRA investing, definitions ... 32 years of knowledge and experience is now in ... community to be able to access 24 hours a ...
(Date:5/27/2015)... CURE® Magazine and the ... to advance research, provide information and support, and raise ... the fifth most common type of cancer, which begins ... grow out of control. , “CURE Magazine provides ... of the cancer experience through digital and print publications, ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Difass USA, ... in the U.S. with its first three flagship products, ... for purchase nationwide through http://www.difassusa.com . , ... health and productivity, but some people struggle with getting ... Dormiva™ is a sleep aid designed to help you ...
(Date:5/27/2015)... Cincinnati, Ohio (PRWEB) May 27, 2015 Cincinnati ... Education & Research for Veterans (CERV) Foundation is proud to ... information fair for women Veterans June 11 at the Freedom ... Reporter Karin Johnson will be the emcee. , This ... and devotion to the nation. The banquet is free ...
Breaking Medicine News(10 mins):Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2
... it eased shoulder pain caused by osteoarthritis , , THURSDAY, Nov. ... pain in arthritis sufferers, a preliminary study found. , "We ... definitive study," said study author Dr. Jasvinder Singh, a staff ... study was small, and more patients needed to be assessed ...
... have discovered that a molecular switch in the protein making ... common forms of lethal breast cancer worldwide. The discovery by ... therapies for the cancer, called locally advanced breast cancer (LABC)., ... LABC may account for 50 percent or more of breast ...
... out of 250 nationwide in annual ,America,s Best,Health Plans, issue, ... ranking of health plans placed Kaiser Permanente of Georgia first ... 250 plans ranked,nationally., The magazine, on newsstands Nov. 5, ... plans -- making it the top,Medicare plan in the state ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) today announced that ... quarter financial results and to,provide a business update. Anyone ... through a live web-cast. The,teleconference and web-cast information is ... Time: 4:30 p.m. Eastern Standard Time (EST) To ...
... Gregory, the Washington,state man who,s spent more than a year ... expects to conclude his odyssey,today at the southernmost city in ... 2006, Gregory set out from his home near the Canadian,border ... his job,with a beverage distributor to accommodate his plans. His ...
... SEATTLE, Nov. 8 Adaptis, a business ... its majority-owned,company, Tela Sourcing, Inc., has purchased ... onshore mailroom, scanning, EDI and PPO routing,services ... Provider,Organizations (PPOs). (Logo: http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) ...
Cached Medicine News:Health News:Botox Offers Shot in Arm for Arthritis Sufferers 2Health News:A molecular switch is linked to a common breast cancer 2Health News:U.S. News & World Report Names Kaiser Permanente Top-Ranked Health Plan in Georgia 2Health News:Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update 2Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2
... macular health. Snellen charts available ... Easy to mount on most ... in a few minutes. Rapid ... Retinal vision testing without refraction ...
Eye Q Lite is ideal for color and red-free imaging used in general clinical and optometric casework such as anterior segmenting and diabetic screening....
The Genesis Camera meets the needs of those with specific requirements that cannot be met by a conventional 'chinrest' type camera....
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: